| Anaemia and iron deficiency. | P Ponikowski (Wroclaw, PL) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Reduction in mortality. | M Metra (Brescia, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Heart failure update 2011. | G Jondeau (Paris, FR) | 31 Aug 2011 | Heart failure / LV dysfunction |
| End-organ protection. | M Gheorghiade (Chicago, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Update on diagnosis and prognostic assessment. | S D Anker (Berlin, DE) | 31 Aug 2011 | Heart failure / LV dysfunction |
| CaM kinase II. | L S Maier (Gottingen, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Pathophysiology of cardiorenal interactions. | C Ronco (Vicenza, IT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Coupling excitation to function - from the stem cell to the patient. | G Hasenfuss (Goettingen, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Therapeutic options. | G S Filippatos (Athens, GR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Relief of dyspnea. | G Cotter (Durham, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Diagnosis of heart failure in a primary health care center: usefulness of framingham clinical criteria, ECG and NT-proBNP | J Comin-Colet (Barcelona, ES) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Novel biomarkers enhance diagnostic differentiation between acute heart failure and pulmonary disease exacerbation in patients presenting with dyspnea | D Farmakis (Piraeus, GR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| New biomarkers for risk identification. | A A Voors (Groningen, NL) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Distinct entity of heart failure in the very elderly as compared with younger based on swedish national heart failure registry | A Holmstrom (Gothenburg, SE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Exhaled acetone as a new biomarker of heart failure diagnosis and short-term prognosis | F G M Braga (Sao Paulo, BR) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Nicotinic receptor N alpha 7 and proinflammatory cytokines in peripheral blood mononuclear cells and parasympathetic drive in patients with systolic heart failure | A M Tomaszek (Wieruszow, PL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Prevention of rehospitalisation. | l Grinfeld (Buenos Aires, AR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Prognostic value of exercise-induced left ventricular systolic dysfunction in hypertensive patients with no angiographic evidence of coronary artery disease | O Prada-Delgado (A Coruna, ES) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Red cell Distribution Width (RDW): a simple and cost effective marker for Acute Heart Failure (AHF) in the Emergency Department | J Searle (Berlin, DE) | 31 Aug 2011 | Heart failure / LV dysfunction |
| How valid are the european society of cardiology echocardiographic diastolic criteria in diagnosing heart failure with normal ejection fraction? | G Mahadavan (Adelaide, AU) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Pathological electrocardiographic changes are associated with adverse remodeling and worse ventricular function in non-ischaemic dilated cardiomyopathy | NA Ismail (High Wycombe, GB) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Prolonged left ventricular twist in cadiomyopathies: a potential link between systolic and diastolic dysfunction | G Pacileo (Naples, IT) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Therapeutic news. | M Metra (Brescia, IT) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Soluble guanylate cyclase activators. | V Mitrovic (Bad Nauheim, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Current indications for resynchronisation therapy. | P E Vardas (Heraklion, GR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Discussant - SHIFT: Selective heart rate reduction with Ivabradine improves left ventricular remodeling and function: insights from the SHIFT-Echocardiography sub-study | B M Pieske (Graz, AT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Heart rate as a target. | JS Borer (New York, US) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Dose titration of the oral potassium binder RLY5016 to maintain normal serum potassium in heart failure and chronic kidney disease patients on aldosterone antagonists | B Pitt (Ann Arbor, US) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Ranolazine in heart failure with preserved ejection fraction. | L S Maier (Gottingen, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Novel natriuretic peptides. | F Ruschitzka (Zurich, CH) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Cardiac myosin activators. | J R Teerlink (San Francisco, US) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Relation between red cell distribution width and 6 minutes walking distance in iron deficient CHF patients; results from FAIR-HF | E Van Craenenbroeck (Edegem, BE) | 31 Aug 2011 | Heart failure / LV dysfunction |
| SHIFT: Selective heart rate reduction with Ivabradine improves left ventricular remodeling and function: insights from the SHIFT-Echocardiography sub-study | J-C Tardif (Montreal, CA) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Is there a mortality risk associated with aspirin use in heart failure? results from a large community based cohort | M Bermingham (Dun Laoghaire, IE) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure. | M Petersen (Copenhagen, DK) | 31 Aug 2011 | Heart failure / LV dysfunction |
| A MRI prospective survey on heart iron and function in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy | A Meloni (Pisa, IT) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Impact of levosimendan treatment, in acute heart failure patients, on mortality and re-hospitalization rate: a long term follow-up | N Bruno (Rome, IT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Telemonitoring in clinical practice. | F Koehler (Berlin, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| How to use aldosterone blockers. | F Zannad (Vandoeuvre Les Nancy, FR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| When conventional heart failure therapy is not enough: angiotensin receptor blocker or aldosterone antagonist? | S Bangalore (New York, US) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Asymptomatic left ventricular systolic dysfunction is prevalent and undertreated prior to diagnosis: a report from the STOP - HF study | G Murtagh (Mullingar, IE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Evaluating the trial strategy for dosage application of betablockers and their impact on the quality of life using the minnesota living with heart failure questionnaire (mlhfq) | dm Melo (Jaboatao Dos Guararapes, BR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Prevention of renal dysfunction with hypertonic saline solution in patients with decompensated heart failure: a prospective, double blind, randomized, placebo-controlled trial. | V Issa (Sao Paulo, BR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Cardiorenal actions of the designer natriuretic peptide, CD-NP, in a severe heart failure model treated with furosemide | E C Costello (Rochester, US) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Effects of metoprolol tartrate versus carvedilol on central aortic pressure in patients with chronic heart failure | V Senthong (Muang, TH) | 31 Aug 2011 | Heart failure / LV dysfunction |
| TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure | G Boerrigter (Rochester, US) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Patient adherence to evidence-based pharmacotherapy in heart failure, a study of patients followed in specialized heart failure outpatient clinics. | A Gjesing (Copenhagen S, DK) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Effects of ivabradine plus beta blockers as first step therapy on heart rate, compliance, quality of life and exercise tolerance in patients with chronic heart failure. | A Macchi (Milano, IT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Restoration of vagal tone by donepezil, on top of losartan treatment, markedly suppresses ventricular dysfunction and improves long-term survival in chronic heart failure rats | M Li (Osaka, JP) | 30 Aug 2011 | Heart failure / LV dysfunction |
| 3',4'-dihydroxyflavonol (DIOHF) attenuates diastolic dysfunction and cardiac remodelling in streptozotocin-induced diabetic m(Ren2)27 rats | F L Khong (Fitzroy, AU) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP. | Z D Kobalava (Moscow, RU) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Clinic blood pressure in stable heart failure patients treated with the dual-acting neprilysin and angiotensin receptor inhibitor LCZ696 | Y Kotovskaya (Moscow, RU) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Discussion. Discussant. | P Jourdain (Pontoise, FR) | 27 Aug 2011 | Heart failure / LV dysfunction |
| Adrenomedullin changes predict survival in dyspneic emergency department patients | WF Peacock (Cleveland, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Plasma renin activity and angiotensinogen M235T polymorphism are determinants of aldosterone escape in patients with systolic heart failure | C Passino (Pisa, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Can the neurohormonal hypotesis be extended to patients with chronic heart failure and preserved left ventricular function? | G Gonzalez Robledo (Barcelona, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Increased levels of fibroblast growth actor 23 (FGF23) in chronic heart hailure patients. | D Gruson (Kraainem, BE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Elevated sympathetic activity mediated by both baroreflex impairment and tonic activation of peripheral chemoreflex in cardiorenal anemia syndrome | N Franchitto (Toulouse, FR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Comparative study on the severity of heart failure based on NYHA heart failure classification and the levels of NT-proBNP, BNP and( NT-proBNP/BNP in pmol/L) | T Shimada (Shizuoka-Shi, JP) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Cost-effectiveness of NT-proBNP-guided therapy in heart failure; results from the TIME-CHF study | S Van Wijk (Maastricht, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Serial measurement of pentraxin-3 is a strong predictor of outcome in heart failure: results from the CORONA and GISSI-HF trials | S Masson (Milan, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure. Results from two large randomized clinical trials | S Masson (Milan, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Use of MR-proANP and NT-proBNP in the timing of beta blocker up-titration in elderly patients with stable chronic heart failure: Data from the CIBIS-ELD study | N Sekularac (Beograd, RS) | 28 Aug 2011 | Heart failure / LV dysfunction |
| The prohormone of B-type natriuretic peptide, proBNP1-108, is secreted by the failing and non-failing human heart | E C Costello (Rochester, US) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Effect of beta blockade up-titration on MR-proANP and copeptin in elderly patients with heart failure and preserved or reduced ejection fraction: Results from the CIBIS-ELD trial | G Loncar (Belgrade, RS) | 29 Aug 2011 | Heart failure / LV dysfunction |
| The association between renal function and mortality risk is attenuated by pro-adrenomedullin and troponin T in outpatients with systolic heart failure: a long term follow up study | H S Bosselmann (Nivaa, DK) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases bioactive BNP level with the improvement of left ventricular mass index in patients with chronic heart failure | T Tsutamoto (Toyosato, JP) | 30 Aug 2011 | Heart failure / LV dysfunction |
| The impact of n terminal pro natriuretic peptide (NT pro BNP) on number needed to screen for heart failure by echocardiography. Prospective observational comparative study | M Al Barjas (London, GB) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Brain natriuretic peptide and renal dysfunction: cardio-renal interactions in patients with acute heart failure | A-G Fruntelata (Bucharest, RO) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Heart rate and cardiac allograft vasculopathy in heart transplant recipients | M T La Rovere (Montescano, IT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Impact of acute cellular rejection in myocardial strain evaluated by means of bidimensional speckle tracking echocardiography in heart transplantation recipients | M Ruiz Ortiz (Cordoba, ES) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Current indications for heart transplantation. | M Grimm (Innsbruck, AT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Post-cardiac transplantation management. | A Gavazzi (Bergamo, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Very late heart transplant rejection is associated with microcirculation injury, complement deposition and progression to cardiac allograft vasculopathy | NULL | 28 Aug 2011 | Heart failure / LV dysfunction |
| Heart transplantation 25 years single centre experience | G Bruschi (Milan, IT) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Impact in survival after change imunossupressive regimens in heart transplantation | M Avila Samuel (Sao Paulo, BR) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Basic and translational science. | B M Pieske (Graz, AT) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Excitation-contraction coupling. | A Zaza (Milan, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Intracellular signalling mechanisms. | R Fischmeister (Chatenay-Malabry, FR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Serum transferrin receptor and its ratio to serum ferritin as the powerful markers in the proper characterization of myocardial iron load and homeostasis | P Leszek (Warsaw, PL) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Myofilament proteins. | J van der Velden (Amsterdam, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Nuclear export of HDAC4 mediates histone demethylation at H3K9 in the promoter region of ANF in response to elevated preload | M Hohl (Homburg, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| The activation of natural killer T cells ameliorates post-infarct heart failure in mice | M A Sobirin (Semarang, ID) | 30 Aug 2011 | Heart failure / LV dysfunction |
| STAT3 preserves dynamic control of mitochondrial NAD(P)H redox state to prevent ROS-production after beta-adrenergic stimulation | M Kohlhaas (Homburg, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Mitochondrial transhydrogenase is a key regulator of antioxidative capacity in cardiac myocytes | A Nickel (Homburg, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Pharmacological inhibition of galectin-3 attenuates adverse cardiac remodeling and heart failure | L Yu (Groningen, NL) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Genetic disruption of galectin-3 prevents adverse cardiac remodeling | L Yu (Groningen, NL) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy | E R Paalberends (Amsterdam, NL) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Reduced maximal force generating capacity in HCM is an intrinsic defect of the sarcomeres | E R Paalberends (Amsterdam, NL) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Deletion of the mineralocorticoid receptor in cardiac myocytes but not in fibroblasts prevents cardiac failure | A Lother (Freiburg, DE) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Changes in endoplasmic reticulum stress are associated with myocardial recovery using mechanical unloading and pharmacological therapy | L E Felkin (Harefield, GB) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Tobacco smoke induces ventricular remodeling associated with an increase in NADPH oxidase activity | PS Azevedo (Botucatu, BR) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Discussant - STICH: Influence of mitral valve repair on survival in the surgical treatment for Ischemic heart failure trial | A Vahanian (Paris, FR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| New assist devices in end-stage heart failure. | P Leprince (Paris, FR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Dyspneoa in emergency department. | A Maisel (Solana Beach, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Biomarkers-guided therapy. | J Januzzi (Boston, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| CD133+ tissue-engineered pulmonary valved stent implantation: a percutaneous technique | A Metzner (Kiel, DE) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Cardiorenal syndrome. | V-P Harjola (Helsinki, FI) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Troponins assessment - does it carry clinical message? | S Blankenberg (Mainz, DE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| High-emergency waiting list for cardiac recipients in france. Single centre five-years experience. | C D'alessandro (Paris Cedex 13, FR) | 31 Aug 2011 | Heart failure / LV dysfunction |
| ECMO therapy for acute heart failure treatment in CICU: integrated management between Cardiologist and Heart Surgeon. | L Cacciavillani (Padova, IT) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Long term results of cardiac resynchronization therapy in heart failure patients who underwent surgical left ventricular epicardial lead Implantation with video assisted thoracoscopy | FG Arlati (Milan, IT) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Extracellular matrix. | J Diez Martinez (Pamplona, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Biomarkers: any news? | D J van Veldhuisen (Groningen, NL) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Prognostic value of baseline NT-proBNP and its interactions with irbesartan treatment in patients with heart failure and preserved ejection fraction: Findings from the I-PRESERVE trial | I S Anand (Edina, US) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Emerging therapeutic options. | G Hasenfuss (Goettingen, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Novel imaging modalitites. | J E Sanderson (Hong Kong, HK) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Atrial dysfunction and chronotropic incompetence. | V Melenovsky (Prague 4, CZ) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Inflammation and left ventricular diastolic dysfunction | C-K Wu (Taipei, TW) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Vascular remodelling and pulmonary hypertension. | C S P Lam (Singapore, SG) | 28 Aug 2011 | Heart failure / LV dysfunction |
| The general clinical approach. | M Senni (Bergamo, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Impact of left ventricular diastolic dysfunction on screening for left ventricular systolic dysfunction using b-type natriuretic peptide: a report from the STOP - HF study | G Murtagh (Mullingar, IE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| SERCA2a gene transfer improves diastolic function in ischemic heart failure | NULL | 30 Aug 2011 | Heart failure / LV dysfunction |
| GDF-15 levels but not NTproBNP levels predict diastolic heart failure in morbid obesity | M Fischer (Regensburg, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| CA 125 as a novel clinical surrogate for heart failure with preserved ejection fraction and an independent predictor for heart failure hospitalization in women | C-L Hung (Taipei, TW) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Epicardial fat is a determinant of diastolic dysfunction | JL Cavalcante (Shaker Heights, US) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Left ventricular diastolic dysfunction and preceding courses of cardiovascular risk factors: a 17-year follow-up study | K van den Hurk (Amsterdam, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Left ventricular diastolic dysfunction and cardiovascular autonomic neuropathy in type 2 diabetes mellitus | C J Magri (Zebbug, MT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Left atrial reservoir function is reduced in diastolic heart failure in a compensated state | M Obokata (Maebashi, JP) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Genetic predisposition in hypertension with normal ejection fraction to oxidative stress is greater than that of controls and increases with the degree of left ventricular diastolic dysfunction | A Fazakas (Budapest, HU) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Efficacy and safety of ivabradine in hemodialysed patients with diastolic heart failure | G Cice (Naples, IT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Coordinated changes in titin phosphorylation increase myofilament stiffness in failing hearts | M Krueger (Bochum, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Left atrial volume index has more accuracy than left atrial diameter index for the diagnosis of heart failure with normal ejection fraction in outpatients. | AJ Lagoeiro Jorge (Marica, BR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| The effect of Losartan plus Hydrochlorothiazide combination therapy on left ventricular diastolic function in patient with hypertension: EDEN Multicenter Trial | K Ishii (Osaka, JP) | 30 Aug 2011 | Heart failure / LV dysfunction |
| What distinguishes restrictive cardiomyopathy from heart failure with preserved ejection fraction? | S Schwartzenberg (Rehovot, IL) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Relationship of left ventricular diastolic function and sympathetic innervation in patients with dilated cardiomyopathy. | A Patrianakos (Heraklion, GR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Diastolic heart failure and reduction in global longitudinal strain: a study with strain imaging and NT-pro-BNP level in patients with rheumatoid arthritis | D Ridjab (Bielefeld, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Percutaneous aortic valve replacement should be preferred therapy for aortic stenosis.: Pro. | M W Bergmann (Hamburg, DE) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Percutaneous aortic valve replacement should be preferred therapy for aortic stenosis.: Pro. | M W Bergmann (Hamburg, DE) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Lessons from acquired heart disease: can they be applied to the failing systemic right ventricle? | P J Mohacsi (Bern, CH) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Left-ventricular assist device should be standard of care for patients with refractory heart failure who are not transplant candidates.: Contra. | P J Mohacsi (Bern, CH) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Left-ventricular assist device should be standard of care for patients with refractory heart failure who are not transplant candidates.: Contra. | P J Mohacsi (Bern, CH) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Myocardial deformation at rest and stress and relationship with aortic stiffness are gender-specific: a dobutamine-stress magnetic resonance imaging study | V Puntmann (London, GB) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Impact the transcatheter aortica valve implantation in patients with severe aortic stenosis with reduced left ventricular ejection fraction | AJ Munoz Garcia (Malaga, ES) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Percutaneous aortic valve replacement should be preferred therapy for aortic stenosis.: Contra. | J B McClurken (Philadelphia, US) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Percutaneous aortic valve replacement should be preferred therapy for aortic stenosis.: Contra. | J B McClurken (Philadelphia, US) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Autophagic myocardial degeneration and improvement of ventricular function in obesity cardiomyopathy as an appropriate model of load-induced heart failure | T Saito (Tokyo, JP) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Altered arterial haemodynamics during exercise in elderly female hypertensives with poor stroke volume reserve | A Sahlen (Stockholm, SE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Pressure volume relationship is related to coronary flow reserve in non-ischemic dilated cardiomyopathy | Q Ciampi (Manocalzati, IT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Non invasive hemodynamic evaluation of patients with acute heart failure in emergency department: impedance cardiography compared with clinical evaluation and B type Natriuretic Peptide (BNP) . | MW Montera (Rio De Janeiro, BR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Prolonged apelin infusion causes sustained increases in cardiac output in humans | G Barnes (Esher, GB) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Left-ventricular assist device should be standard of care for patients with refractory heart failure who are not transplant candidates.: Pro. | R Starling (Cleveland, US) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Left-ventricular assist device should be standard of care for patients with refractory heart failure who are not transplant candidates.: Pro. | R Starling (Cleveland, US) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure: a randomized, controlled trial | M Shigekiyo (Tokushima City, JP) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Left ventricular geometry of normotensive progeny of patients with hypertension | A Mbakwem (Idi Araba, NG) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Acute benefical impact of adaptive servo ventilation on hemodynamic data in heart failure patients with Cheyne-Stokes respiration | M Miyata (Fukushima, JP) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Diagnostic value of Doppler transthoracic echocardiography in the estimation of left ventricular filling pressure in patients with severe symptomatic systolic heart failure | B Gellen (Creteil, FR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Aortic stiffness and left atrial volume index in adult dialyzed patients: dependence - compliance and pressure | A Wysokinski (Lublin, PL) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Invasive evaluation of whether decline in pressure after initial immediate increment on improving AV delay of CRT is due to vasodilatation or decline in cardiac function | P Pabari (London, GB) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Obese heart failure patients have less cardiac impairment than thinner counterparts | L-B Tan (Leeds, GB) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Bones. | P Rozentryt (Zabrze, PL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Liver. | P de Groote (Lille Cedex, FR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Two hour plasma glucose is associated with noninvasively assessed left ventricular filling pressure, 6-minute walking distance and NT-proBNP in chronic systolic heart failure | M Egstrup (Copenhagen, DK) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Mitogen-activated protein kinases and nuclear factor-kappaB participation in skeletal muscle response to oxidative stress in rats with heart failure | P F Martinez (Botucatu, BR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Predicting survival in chronic heart failure: a risk score based on 47886 patients from 31 studies | S J Pocock (London, GB) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Impact of tricuspid regurgitation on survival in patients with chronic heart failure- a long-term observational study | M Huelsmann (Vienna, AT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Why and how do patients with heart failure die? Insights from the TIME-CHF trial | H P Brunner-La Rocca (Maastricht, NL) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Prognostic role of red cell distribution width (RDW) variations among patients with chronic heart failure | N Pezzali (Brescia, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Does hypertension affect outcome of patients with acute decompensated heart failure (data from the AHEAD registry)? | M Felsoci (Brno, CZ) | 28 Aug 2011 | Heart failure / LV dysfunction |
| The six- minute walking test is still an excellent tool for ongoing monitoring of a population of elderly patients with chronic heart failure. | A B Scardovi (Roma, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Determinants and prognostic impact of improvement in left ventricular ejection fraction after hospitalisation for systolic heart failure. | S Brenner (Wuerzburg, DE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Prognostic impact of pulmonary function in systolic heart failure | S Brenner (Wuerzburg, DE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Right ventricular function predicts chronic kidney disease and survival in patients with chronic systolic heart failure | F L Dini (Pisa, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Prognostic significance of change in diastolic function defined by mitral doppler - a prospective cohort study - the Tromso Study 1994-2009 | G Heggelund (Tromso, NO) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Anaemia independently predicts outcome in patients with heart failure with preserved and reduced ejection fraction: a MAGGIC sub-group analysis. | KK Poppe (Auckland, NZ) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Impact of functional tricuspid regurgitation on long-term survival and heart failure in patients with functional mitral regurgitation and left ventricular dysfunction | E Agricola (Segrate, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| The prognostic value of a new tissue Doppler parameter in patients with heart failure | C Mornos (Timisoara, RO) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Relation of serum sodium concentration to mortality in a large spectrum of heart failure patients with preserved and reduced ejection fraction: results from the MAGGIC meta-analysis | D Rusinaru (Amiens Cedex 1, FR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Additive prognostic value of diastolic dysfunction and coronary flow reserve in non-ischemic dilated cardiomyopathy | Q Ciampi (Manocalzati, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| High sensitivity troponin T serum levels and prognosis in ambulatory patients with heart failure | M De Antonio Ferrer (Barcelona, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| The independent prognostic value of hyponatremia in a cohort of heart failure patients: analysis from the duke databank for cardiovascular disease | L Bettari (Brescia, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| The obesity paradox in heart failure: is aetiology the key? | E Zamora Serrallonga (Badalona, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Impaired fasting glucose: a predictor of increased morbidity and mortality in patients with heart failure | I Gotsman (Jerusalem, IL) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Patterns of acute heart failure in nonagenarians | H Dossi (Paris, FR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| VE/VCO2 slope: What is the most powerful independent predictor of survival: overall, initial or final VE/VCO2 slopes? A study in 786 consecutive patients with left ventricular systolic dysfunction | A Musschoot (Lille, FR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Prognostic additive value of high sensitivity soluble ST2 in ambulatory heart failure patients | A Bayes Genis (Badalona, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Soluble ST2 predicts outcome in heart failure of ischemic aetiology | K Broch (Oslo, NO) | 28 Aug 2011 | Heart failure / LV dysfunction |
| The prognostic value of troponins in patients with heart failure: a meta-analysis | E Gardini (Forli, IT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Delayed rocovery in peripartum cardiomyopathy: An indication for long-term follow-up and sustained therapy | Murat Biteker (Istanbul, TR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Role of lung impedance monitoring in the outpatient clinic for predicting and preventing of hospitalizations patients with chronic heart failure | S R Meisel (Hadera, IL) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Mid-region proHormone adrenomedullin identifies acutely dyspneic emergency department patients with high 90 day mortality: results from the Biomarkers in Acute Heart Failure (BACH) trial | R M Nowak (Detroit, US) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Frequency and timing of heart failure readmissions in the netherlands | J A Overbeek (Utrecht, NL) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Recent in-hospital mortality trends among patients with heart failure in the netherlands | J A Overbeek (Utrecht, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Depressive symptoms and antidepressants in heart failure: a prospective long-term mortality follow-up study | C Diez (Badalona, ES) | 30 Aug 2011 | Heart failure / LV dysfunction |
| INTERMACS profiles predict postoperative outcomes in critically ill patients undergoing urgent heart transplantation. Data from the Spanish national heart transplant registry | E Barge Caballero (A Coruna, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Comparison of postoperative outcomes of critically ill patients bridged to urgent heart transplantation with VADs or with conventional therapy: data from the spanish national heart transplant registry | E Barge Caballero (A Coruna, ES) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Rapidly progressive coronary artery vasculopathy in heart transplant recipients: a volumetric intravascular ultrasound evaluation | K Uno (Cleveland, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Impact of clinical and echocardiographic response to cardiac resynchronization therapy on long-term survival | M Bertini (Ferrara, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Influence of diabetes, sex, and ejection fraction on the risk of death in patients with heart failure: results from the MAGGIC individual patient meta-analysis | M Martinez-Selles (Madrid, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Bioelectrical impedance-derived oedema index provides 6-month prognostic value in patients hospitalised due to acute heart failure | S-J Chen (Keelung City, TW) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Baseline blood urea nitrogen as a marker for predicting cardiac events in patients hospitalized for acute heart failure syndrome - beyond other renal variables - | T Aokage (Tokyo, JP) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Brain natiuretic neptide in patients with type 2 diabetes and normal ejection fractions predicts all-cause mortality | B Szwejkowski (Dundee, GB) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Red cell distribution width is better for predicting short-term and long-term outcomes than hemoglobin in acute onset of congestive heart failure | Y Dai (Shanghai, CN) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Right ventricular ejection fraction is an independent prognostic predictor in patients with ischemic heart disease | RL Braam (Apeldoorn, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Clinical outcomes in advanced acute heart failure (AHF) patients stratified by INTERMACS classification | D Bresson (Bron, FR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Severe low-cardiac output heart failure patients bridged to beta-blockade by enoximone: prolonged survival without heart transplantation | AA Constantinescu (Rotterdam, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Albuminuria predicts the mortality in heart failure patients with preserved ejection fraction independent of glomerular filtration rate - an interim analysis of the CHART-2 study- | M Miura (Sendai, JP) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Stratifying prognosis in heart failure: nutritional status versus body mass index. | P Gastelurrutia (Badalona, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Current recommendations from the ESC Guidelines. | K Dickstein (Stavanger, NO) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Basic science. | A M Shah (London, GB) | 29 Aug 2011 | Heart failure / LV dysfunction |
| What do the Guidelines say? | D J van Veldhuisen (Groningen, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| What do the Guidelines say? | J L Lopez-Sendon (Madrid, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Cardiac resynchronisation therapy-defibrillator should usually be preferred to cardiac resynchronisation therapy-pacing.: Contra. | J G F Cleland (Kingston Upon Hull, GB) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Cardiac resynchronisation therapy-defibrillator should usually be preferred to cardiac resynchronisation therapy-pacing.: Contra. | J G F Cleland (Kingston Upon Hull, GB) | 29 Aug 2011 | Heart failure / LV dysfunction |
| High heart rate: maximise beta-blockers rather than add ivabradine.: Contra. | K Swedberg (Goteborg, SE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| High heart rate: maximise beta-blockers rather than add ivabradine.: Contra. | K Swedberg (Goteborg, SE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Place of devices? | A Mebazaa (Paris Cedex 10, FR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Persisting low output. | A Mebazaa (Paris Cedex 10, FR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Have medical treatment options improved? | P Ponikowski (Wroclaw, PL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Discussant - EMPHASIS-HF. The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure: An analysis of the High-risk groups in the study population | P Ponikowski (Wroclaw, PL) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Pathophysiology. | M Metra (Brescia, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Spinal cord stimulation. | HN Sabbah (Detroit, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Results of a randomized clinical study evaluating nurse-driven telemedicine interventions for high risk chronic heart failure patients with frequent rehospitalizations | H Persson (Stockholm, SE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Medical therapy. | G Jondeau (Paris, FR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Novel implantable devices for New York Heart Association I-III heart failure patients. | M R Cowie (London, GB) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Worsening renal function in heart failure; prognostic markers and effect of drugs. | M R Cowie (London, GB) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Telemonitoring. | S D Anker (Berlin, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| SERCA gene transfer: CUPID trial. | B H Greenberg (San Diego, US) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Drug treatment. | H Krum (Melbourne, AU) | 29 Aug 2011 | Heart failure / LV dysfunction |
| High heart rate: maximise beta-blockers rather than add ivabradine.: Pro. | H Krum (Melbourne, AU) | 29 Aug 2011 | Heart failure / LV dysfunction |
| High heart rate: maximise beta-blockers rather than add ivabradine.: Pro. | H Krum (Melbourne, AU) | 29 Aug 2011 | Heart failure / LV dysfunction |
| SHIFT: Relationship between heart rate and health related quality of life. Results from SHIFT | I Ekman (Goteborg, SE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| My top ten papers from the European Journal of Heart Failure 2009-2010. | W H van Gilst (Groningen, NL) | 31 Aug 2011 | Heart failure / LV dysfunction |
| The frequency, serial changes and clinical characteristics of cardiac troponin release in patients with acute heart failure syndrome | B Gorenek (Eskisehir, TR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Role of nuclear cardiology and cardiac computed tomography. | S R Underwood (London, GB) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Which imaging techniques? | U Sechtem (Stuttgart, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Assessing the clinical impact of CCM: past and ongoing clinical studies. | M Borggrefe (Mannheim, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Diabetes. | B M Pieske (Graz, AT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Vagal nerve stimulation. | P J Schwartz (Pavia, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Discussant - SHIFT: Relationship between heart rate and health related quality of life. Results from SHIFT | E Erdmann (Koeln, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Right ventricular function is a determinant of clinical response to cardiac resynchronization therapy over long-term | LE Sade (Ankara, TR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Percutaneous, intra-myocardial injection of unselected bone marrow-derived mononuclear cells via NOGA-XP significantly improves ejection fraction in post-infarct patients | M W Bergmann (Hamburg, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Role of echocardiography. | W G Daniel (Erlangen, DE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Acute kidney injury and outcomes in acute decompensated heart failure in Korea | MS Shin (Incheon, KR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Valvular heart disease. | G Sinagra (Trieste, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Chronic heart failure patients are vitamin D deficient and hyperparathyroid, levels of each relate to markers of severity | K Witte (Leeds, GB) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Stem cell tissue engineering for the failing heart. | G Steinhoff (Rostock, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Admission blood pressure determines medical treatment and clinical outcomes of patients with acute decompensated heart failure: from KorHF investigators | SH Jo (Anyang-Si, Gyeonggi-Do, KR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Invasive and non-invasive monitoring. | J T Parissis (Athens, GR) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Impact of diabetes mellitus on chronic life saving therapies in patients hospitalized for acute heart failure : an ALARM-HF survey sub-analysis | J T Parissis (Athens, GR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Discussant - SMART-AV: The role of electrical delay (QLV) to predict left ventricular reverse remodeling with cardiac resynchronization therapy | C Linde (Stockholm, SE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Definitions. | G S Filippatos (Athens, GR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| General Registry: Heart Failure. | A P Maggioni (Florence, IT) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Prevalence of heart failure in Beta thalassaemia major patients | A Rohani (Yasooj, IR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Pathophysiology: impact on management. | JS Hochman (New York, US) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Mitochondrial reactive oxygen species. | C Maack (Homburg/Saar, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Devices for treating arrhythmias and heart failure. | C W Israel (Bielefeld, DE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Imposible diuresis. | E A Lopez De Sa Y Areses (Madrid, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Gene transfer. | R J Hajjar (New York, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Surgical management. | A Pitsis (Thessaloniki, GR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Peripartum cardiomyopathy. | D Hilfiker-Kleiner (Hannover, DE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Admission glycaemia in acute heart failure - a different story in diabetics and non-diabetics | H Martins (Coimbra, PT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Galectin 3 predicts mortality and response to statin therapy in chronic heart failure | L Gullestad (Oslo, NO) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Disparity between matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 correlated with the severity and adverse prognosis in patients with heart failure and systolic dysfunct | T Morishita (Yoshida-Gun, JP) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Multimarker strategy for the prediction of 6-month major adverse cardiac events in patients with and without congestive heart failure after acute myocardial infarction | J H Lee (Daegu, KR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Insulin resistance. | M Mamas (Manchester, GB) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Wine consumption in chronic heart failure: biohumoral correlates and impact on outcomes | R Latini (Milan, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Myocardial myostatin and follistatin protein expression in spontaneously hypertensive rats with heart failure | R L Damatto (Botucatu, BR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Markers of malnutrition in hospitalized patients with heart failure | JL Bonilla Palomas (Cordoba, ES) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Does malnutrition determined by the Mini Nutritional Assessment (MNA) test retain its influence on long-term mortality in hospitalized patients with heart failure? | JL Bonilla Palomas (Cordoba, ES) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Role of cardiac myocardial resonnance imaging. | M Desai (Cleveland, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Gut. | A Sandek (Berlin, DE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| A simple diastolic echocardiographic measure to identify patients who will develop cardiotoxicity after cancer target-therapy. | N Gaibazzi (Parma, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| A novel Tissue Doppler parameter predict cardiac death in patients with heart failure | C Mornos (Timisoara, RO) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Progressive remodelling to heart failure. | J Bauersachs (Hannover, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Myocyte alterations. | Z Papp (Debrecen, HU) | 28 Aug 2011 | Heart failure / LV dysfunction |
| SMART-AV: The role of electrical delay (QLV) to predict left ventricular reverse remodeling with cardiac resynchronization therapy | M R Gold (Charleston, US) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Devices for end-stage heart failure. | L Warner Stevenson (Boston, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Implantable cardioverter-defibrillator and cardiac resynchronisation therapy. | J Holzmeister (Zurich, CH) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Genetic variants associated to reverse remodelling after cardiac resynchronization therapy | R De Maria (Milan, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Cardiac markers and hemodynamics after intrahepatic portosystemic shunt in liver cirrhosis | R Pudil (Hradec Kralove, CZ) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Optimal application of telemonitoring. | A Mortara (Monza, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Congestive heart failure and euthyroid sick syndrome | I Shatynska-Mytsyk (Lviv, UA) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Incidence of cardiotoxicity of Trastuzumab in Her2Neu positive breast cancer patients: a retrospective cohort study | C Liesting (Dordrecht, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Cardiac resynchronisation therapy-defibrillator should usually be preferred to cardiac resynchronisation therapy-pacing.: Pro. | JYS Chan (Hong Kong, HK) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Cardiac resynchronisation therapy-defibrillator should usually be preferred to cardiac resynchronisation therapy-pacing.: Pro. | JYS Chan (Hong Kong, HK) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Pulmonary hypertension. | O Sitbon (Clamart, FR) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Grown-up congenital heart disease. | M Chessa (San Donato Milanese, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Redox regulation in calcium and sodium handling. | S Wagner (Goettingen, DE) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Mechanical support. | E Roig (Barcelona, ES) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Coronary interventions. | M Lesiak (Poznan, PL) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Non-viral gene therapy JVS-100 provides functional benefit to patients with ischemic heart failure | M S Penn (Akron, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Relationship between RANKL and neuroendocrine activation in elderly males with heart failure | G Loncar (Belgrade, RS) | 29 Aug 2011 | Heart failure / LV dysfunction |
| A potential cross-talk between fat and bone in patients with chronic heart failure | G Loncar (Belgrade, RS) | 29 Aug 2011 | Heart failure / LV dysfunction |
| GDF-15 in emergency patients with acute dyspnea | A Slagman (Berlin, DE) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Contributions of peak expiratory flow to assessment of acute decompensated heart failure: insights from ASCEND-HF | J A Ezekowitz (Edmonton, CA) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Single centre long term follow-up of undersized mitral annuloplasty for mitral regurgitation in end-stage dilated cardiomyopathy | G Bruschi (Milan, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Incidence and predictors of postoperative Heart Failure(HF) in patients undergoing elective noncardiac surgery | A Rajamanickam (Wilmington, US) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Gender differences in the prevalence of asymptomatic left ventricular dysfunction and heart failure in the elderly: a population-based study in central Italy | A Boccanelli (Roma, IT) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Characterization of left ventricular lead position and its relation with myocardial scar region | Y-M Cha (Rochester, US) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Effects of cardiac resynchronization therapy in patients with systolic heart failure: a meta-analysis of randomized controlled trials across all NYHA functional class | S G Miriuka (Buenos Aires, AR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Impact of radiofrequency catheter ablation on echocardiographic and cardiopulmonary performance in patients with ventricular extrasystolic beats and suspected arrhythmia-induced cardiomyopathy | T Krynski (Warsaw, PL) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Vagus nerve stimulation improves left ventricular function in heart failure: results of a 6 month investigation with a cross-over design in dogs with experimental heart failure | J Hamann (St. Paul, US) | 30 Aug 2011 | Heart failure / LV dysfunction |
| Influence of T786C polymorphism of the endothelial nitric oxide synthase gene on insulin resistance in patients with ischemic and non ischemic heart failure | C Vecoli (Pisa, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Impact of high risk pregnancy on left ventricular function during peripartum period: from the toyota peripartum cardiomyopathy study | H Umeda (Toyota, JP) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Gender-dependent characteristics of sleep-disordered breathing in patients with chronic heart failure | H Woehrle (Ulm, DE) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Sleep at high altitude (2880m) and pulmonary pressure in patients with left ventricular dysfunction | G Mazzuero (Omegna, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Association of transmyocardial gradient of n-3 polyunsaturated fatty acid with the washout rate of Tc-99msestamibi in patients with idiopathic dilated cardiomyopathy | M Wakasa (Kahoku-Gun, JP) | 29 Aug 2011 | Heart failure / LV dysfunction |
| 3-methylglutaconic aciduria (3MGA) in adult patients with left ventricular systolic dysfunction (LVSD) | M Wakasa (Kahoku-Gun, JP) | 29 Aug 2011 | Heart failure / LV dysfunction |
| A new integrated approach to improve left ventricular electromechanical activation during right ventricular septal pacing | G Pastore (Albignasego, IT) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Stimulation of angiogenesis by inhibition of the protein tyrosine phophatase 1B | M Besnier (Rouen Cedex, FR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Uric acid as a predictor of poor myocardial perfusion, left ventricular systolic function and long-term outcomes in patients with STEMI without previously diagnosed heart failure | M Roik (Warszawa, PL) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Correlation between electrocardiographic and echocardiographic changes observed after LVAD implantation in patients with advanced heart failure | R Tayal (Newark, US) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Impact of age on clinical profile, management, and mortality in patients hospitalized with acute decompensated heart failure: an analysis from the ATTEND registry | M Mizuno (Tokyo, JP) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Mechanical dyssynchrony predicts acquired left ventricle dysfunction after right ventricle apex pacing | S Sakurai (Nagakute, JP) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Head-to-head comparison of different delivery methods of autologous bone marrow progenitor cells in chronic ischaemic heart failure | A Mozid (London, GB) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Integrated area desaturation index can estimate severity of heart failure with severity of sleep apnea | N Takama (Isesaki, JP) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Existence of masked obstructive sleep apnea after adaptive servo-ventilation therapy in heart failure patient with central sleep apnea | N Takama (Isesaki, JP) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Comparison of prognostic variables between two cohorts of outpatients with heart failure in the last two decades | A J Mansur (Sao Paulo, BR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| The change of nutritional status influences the duration of hospital stay on patients with systolic heart failure | S Namiuchi (Sendai, JP) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Evaluation of domain-specific cognitive defects in patients with chronic heart failure | M Watanabe (Melbourne, AU) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Experimental myocardial infarction versus doxorubicin-induced cardiotoxicity as interventions to build up ovine models of chronic heart failure: comparative characteristics. | A B De Lorenzi (La Plata, AR) | 29 Aug 2011 | Heart failure / LV dysfunction |
| State of the Art - Probing prognosis in heart failure | D R Wagner (Luxembourg, LU) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Palliative care in chronic heart failure | M A Denvir (Edinburgh, GB) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Levosimendan out of critical care units, efficacy, safety and perfusion protocols | M Lazaro Salvador (Toledo, ES) | 29 Aug 2011 | Heart failure / LV dysfunction |
| Stress (Takotsubo) cardiomyopathy and heart failure: clinical predictors | I Nunez-Gil (Madrid, ES) | 31 Aug 2011 | Heart failure / LV dysfunction |
| Tubular markers in heart failure; can we finally monitor renal function adequately? | CAJM Gaillard (Bilthoven, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |
| Panel discussion. | A Cohen-Solal (Paris, FR), M R Cowie (London, GB), CAJM Gaillard (Bilthoven, NL) | 28 Aug 2011 | Heart failure / LV dysfunction |